Longboard Pharmaceuticals, Inc. (LBPH) has disclosed a new risk, in the International Operations category.
Longboard Pharmaceuticals, Inc. faces significant business and operational challenges as it pursues international expansion for its global Phase 3 program for bexicaserin. The company must navigate complex legal and regulatory landscapes, which include varying privacy and tax laws, import/export restrictions, and the necessity for governmental permits. Additionally, Longboard Pharmaceuticals could encounter difficulties in managing overseas operations and ensuring the acceptance of foreign clinical trial data by different regulatory authorities. These risks, compounded by potential political and economic instability in target markets, underscore the heightened uncertainties Longboard Pharmaceuticals confronts in its venture outside the United States.
Overall, Wall Street has a Strong Buy consensus rating on LBPH stock based on 8 Buys.
To learn more about Longboard Pharmaceuticals, Inc.’s risk factors, click here.
